ABC News: Rare cases of COVID returning pose questions for Pfizer pill
As COVID-19 cases rise some cases are returning after usage of Pfizer’s antiviral pill, putting the efficacy of the medication into question. The drug was first authorized in December 2021 for adults with preconditions based on a study where 1,000 adults took the pill. Since then the United States government has spent $10 billion to treat 20 million people with the medication. But now doctors have reported rare cases of symptoms returning a few days after taking the pills. The Food and Drug Administration has advised against patients who relapsed receiving a second course of Pfizer pills because the returning symptoms don’t seem to be severe. Some experts believe Paxlovid’s strength against the virus has wavered since Omicron became the primary variant because the original efficacy tests were done on patients with the Delta variant, not Omicron. The full article by Matthew Perrone can be read here on ABC News. For more on COVID-19 click here.